Related Experiment Video
Updated: May 2, 2026

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
Published on: May 11, 2020
Testing a new formulation for Peste des Petits Ruminants vaccine in Ethiopia
Ana Carina Silva1, Martha Yami2, Geneviève Libeau3
1Instituto de Biologia Experimental e Tecnológica (IBET), Animal Cell Technology Unit, Apartado 12, P-2781-901 Oeiras, Portugal; Instituto de Tecnologia Química e Biológica-Universidade de Lisboa (ITQB-UNL), Animal Cell Technology Unit, Apartado 12, P-2781-901 Oeiras, Portugal.
Abstract:
In this paper extended tests on a new candidate formulation for Peste des Petits Ruminants (PPR) vaccine carried out at National Veterinary Institute (NVI) in Ethiopia are presented. This work was performed in the frame of the VACNADA project from GALVmed which aimed at procuring vaccines against neglected veterinary diseases to African vaccine producing laboratories, in particular PPR. After the eradication of Rinderpest, Peste des Petits Ruminants became the next veterinary disease on target for elimination, requiring an effective and thermostable vaccine. In this work a Tris/Trehalose formulation was evaluated in thermal stability studies in comparison to the current used formulation of the live attenuated PPR vaccine, the Weybridge medium. The extended results presented herein show an increased thermal stability of the vaccine, especially at 37 and 45 °C, as expected from previously published results (Silva A.C. et al., 2011). Furthermore, during the course of this project, the NVI teams have clearly demonstrated ability to produce higher quality PPR vaccines after a successful transfer of the technology. These results should significantly enhance the utility of the vaccine in the eradication of PPR.
More Related Videos
07:40Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications
Published on: June 29, 2020
06:26Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023